Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

250 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer.
ten Bokkel Huinink WW, Bergman B, Chemaissani A, Dornoff W, Drings P, Kellokumpu-Lehtinen PL, Liippo K, Mattson K, von Pawel J, Ricci S, Sederholm C, Stahel RA, Wagenius G, Walree NV, Manegold C. ten Bokkel Huinink WW, et al. Among authors: manegold c. Lung Cancer. 1999 Nov;26(2):85-94. doi: 10.1016/s0169-5002(99)00067-7. Lung Cancer. 1999. PMID: 10568679 Clinical Trial.
A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.
Manegold C, Drings P, von Pawel J, Ricci S, Dornoff W, van Walree N, ten Bokkel Huinink W, Chemaissani A, Stahel P, Bergman B, Wagenius G, Sederholm C, Mattson K, Liippo K, Kellokumpu-Lehtinen P. Manegold C, et al. Semin Oncol. 1997 Jun;24(3 Suppl 8):S8-13-S8-17. Semin Oncol. 1997. PMID: 9207310 Clinical Trial.
Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer.
Manegold C, Bergman B, Chemaissani A, Dornoff W, Drings P, Kellokumpu-Lehtinen P, Liippo K, Mattson K, van Pawel J, Ricci S, Sederholm C, Stahel RA, Wagenius G, van Walree N, ten Bokkel-Huinink W. Manegold C, et al. Ann Oncol. 1997 Jun;8(6):525-9. doi: 10.1023/a:1008207731111. Ann Oncol. 1997. PMID: 9261520 Free article. Clinical Trial.
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH. Giaccone G, et al. Among authors: manegold c. J Clin Oncol. 2004 Mar 1;22(5):777-84. doi: 10.1200/JCO.2004.08.001. J Clin Oncol. 2004. PMID: 14990632 Clinical Trial.
Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.
Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold C, Palmer MC, Gregor A, Nguyen B, Niyikiza C, Einhorn LH. Sandler AB, et al. Among authors: manegold c. J Clin Oncol. 2000 Jan;18(1):122-30. doi: 10.1200/JCO.2000.18.1.122. J Clin Oncol. 2000. PMID: 10623702 Clinical Trial.
250 results